BofA raised the firm’s price target on Novavax (NVAX) to $8 from $7 and keeps an Underperform rating on the shares. The firm updated its model with a refreshed COVID build more reflective of current indicated populations and vaccination rates and updated 2026 revenue and operating expense forecasts per new guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX: